Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2
about
DNA plasmid vaccine carrying Chlamydia trachomatis (Ct) major outer membrane and human papillomavirus 16L2 proteins for anti-Ct infection.Intracellular delivery of messenger RNA by recombinant PP7 virus-like particles carrying low molecular weight protamine.Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV)Optimized Formulation of a Thermostable Spray-Dried Virus-Like Particle Vaccine against Human PapillomavirusProgress and prospects for L2-based human papillomavirus vaccinesEngineering virus-like particles as vaccine platformsDesign of virus-based nanomaterials for medicine, biotechnology, and energy.Phage-Enabled Nanomedicine: From Probes to Therapeutics in Precision MedicineNovel miR-122 delivery system based on MS2 virus like particle surface displaying cell-penetrating peptide TAT for hepatocellular carcinoma.Developments in L2-based human papillomavirus (HPV) vaccines.Characterization of a spray-dried candidate HPV L2-VLP vaccine stored for multiple years at room temperature.A shared N-terminal hydrophobic tail for the formation of nanoparticulates.A novel candidate MS2 phage VLP vaccine displaying a tandem HPV L2 peptide offers similar protection in mice to Gardasil-9.Broadly neutralizing antiviral responses induced by a single-molecule HPV vaccine based on thermostable thioredoxin-L2 multiepitope nanoparticles.Progress Toward the Clinical Translation of Bioinspired Peptide and Protein Assemblies.A Virus-Like-Particle immunotherapy targeting Epitope-Specific anti-xCT expressed on cancer stem cell inhibits the progression of metastatic cancer in vivo.
P2860
Q33779429-6CE23C81-B81F-49E9-931F-87C231BC2742Q36032757-FD9294E8-5F79-44CB-BF51-8A566A53CB12Q36240497-21F19ADB-8BA3-498F-94AD-178B20E3EBD1Q36858686-405AED01-051F-40BB-8CD8-9A45EEF53380Q37014047-2BB1BEF2-439F-40F6-B2BB-CF1DE11DBCE0Q37172342-B9181423-50BE-4428-8FFF-CFD28EAE9E4DQ37346447-F515AC22-EBBA-4986-9978-C7FCD3439FFFQ37644025-67B5E8D0-A35D-4B4C-8116-E3993C6E1C02Q37644875-E41B5D4B-120E-4DB0-8409-04F09879B6E6Q39021001-14C74FD7-D8D5-48AE-8726-5BDBAE9DDBF9Q40117882-7BE5C1D7-3439-4F8D-8A62-6943BB4137D6Q40585281-5BE445C2-2FF3-4651-99F0-CD95E1F6C627Q41931899-5E1F0734-B3CF-43E7-B30F-55C26CC8C6B8Q47110564-F0B5A6F8-09A0-4D1A-85FB-EC8193122064Q47370297-7050714D-D22B-41FE-845D-C9A9A5BAFA72Q55264209-B2D55B0B-FD1F-4820-B09C-33AC858778CA
P2860
Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Preclinical refinements of a b ...... g the minor capsid protein, L2
@ast
Preclinical refinements of a b ...... g the minor capsid protein, L2
@en
type
label
Preclinical refinements of a b ...... g the minor capsid protein, L2
@ast
Preclinical refinements of a b ...... g the minor capsid protein, L2
@en
prefLabel
Preclinical refinements of a b ...... g the minor capsid protein, L2
@ast
Preclinical refinements of a b ...... g the minor capsid protein, L2
@en
P2093
P2860
P1433
P1476
Preclinical refinements of a b ...... g the minor capsid protein, L2
@en
P2093
Bryce Chackerian
Carolina Andrea A Escobar
David S Peabody
Denis Wafula
Ebenezer Tumban
Julianne Peabody
Pavan Muttil
P2860
P304
P356
10.1016/J.VACCINE.2015.05.016
P407
P577
2015-05-21T00:00:00Z